First human tests begin for new herpes prevention vaccine
NCT ID NCT05432583
Summary
This is an early-stage study to test the safety and immune response of a new vaccine, called BNT163, designed to prevent genital lesions caused by herpes simplex virus type 2 (HSV-2). The trial involves 318 healthy adults and people with a history of recurrent genital herpes. Researchers will give participants three shots of the vaccine or a placebo and closely monitor for side effects and the body's antibody response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENITAL HERPES SIMPLEX TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Accellacare PMG Research Wilmington LLC
Wilmington, North Carolina, 28401, United States
-
Accellacare Raleigh Medical Group
Raleigh, North Carolina, 27609, United States
-
Alliance for Multispecialty Research, LLC
Tempe, Arizona, 85281, United States
-
CTI Clinical Research Center
Cincinnati, Ohio, 45212, United States
-
Great Lakes Clinical Trials - Flourish Research
Chicago, Illinois, 60640, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.